Where does Asklepios Biopharmaceutical, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Asklepios Biopharmaceutical, Inc. ranks #30,893 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Asklepios Biopharmaceutical, Inc. hold?

Asklepios Biopharmaceutical, Inc. holds 8 US utility patents granted between 2016 and 2025, spanning 6 technology areas.

What is Asklepios Biopharmaceutical, Inc.'s Innovation Score?

Asklepios Biopharmaceutical, Inc. has an Innovation Score of 45.5 out of 100 (top 23% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Asklepios Biopharmaceutical, Inc.'s patent grant rate increasing or decreasing?

Asklepios Biopharmaceutical, Inc.'s recent grant velocity is +150% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Asklepios Biopharmaceutical, Inc.'s patents?

Asklepios Biopharmaceutical, Inc.'s patents average 15.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Asklepios Biopharmaceutical, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Asklepios Biopharmaceutical, Inc.

Q: What technology areas does Asklepios Biopharmaceutical, Inc. focus on?

Asklepios Biopharmaceutical, Inc.'s top technology area is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media) with 8 patents, ranking #1,253 of 4,144 assignees active in that subclass. Grants appear in 6 CPC subclasses total.

USPTO PatentsView assignee record - 8 granted patents across 6 technology areas, recorded in grant years 2016–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Asklepios ranks #30,893 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 6 technology areas.

#30,893
of 49,997 US assignees by volume: Top 23%
by Innovation Score (45.5/100): 15.4
avg claims per patent: +150%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R30893 · US Corporation #30,893 · 8 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 8 grants
MID-PACK #30,893/49,997
PHOTO-FINISH ART Research AND…
CPC-NARROW C12N · 6 areas
INNOV-PAR 45.5/100
CLAIMS-RICH 15.4 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +150% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: ART Research AND Technology, L.L.C. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Asklepios’s 45.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.6 pts (17%) Velocity 20.0 pts (44%) Breadth 8.7 pts (19%) Claim depth 9.2 pts (20%)

Qualcomm Incorporated · highest

85
Asklepios Biopharmac… · this assignee

45
3D Lighting… · lowest

7

What this shows Asklepios's Innovation Score is 45.5/100 (top 23% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Asklepios?

Each dot is one of Asklepios’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Asklepios’s own 15.4 claims/patent is at or below the 17.5 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Asklepios vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Asklepios's grants concentrate

Asklepios Biopharmaceutical, Inc. is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media). Peak complete grant year is 2022 (4 grants) versus a trough of 1 in 2016. By volume, Asklepios sits between ART Research AND Technology, L.L.C. and Aspinity, Inc..

Asklepios's three-year grant acceleration

Asklepios Biopharmaceutical, Inc. shows 5 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

ART Research AND…

8
ASA

8
Asahi Medical

8
Asia Pacific Fuel…

8
ASM Assembly Syst…

8
ASM Assembly Syst…

8
AsociaciÓN Centro…

8
Aspinity

8
Asklepios Biophar… ◀

8

What this shows Asklepios holds 8 patents at rank #30,804, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Asklepios

By rank, the assignees closest to #30,804 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Asklepios's primary technology class.

Asklepios's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

45 Top 23% higher than 77% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Asklepios Biopharmaceutical, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	1	12.5%
2019	1	12.5%
2022	4	50.0%
2024	1	12.5%
2025partial year	1	12.5%

Which technologies does Asklepios Biopharmaceutical, Inc. patent most?

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 8

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 6

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 5

C07K - Peptides 3

C40B - Combinatorial CHEMISTRY; Libraries, e.g. Chemical Libraries 1

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 1

Top 6 of 6 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Asklepios Biopharmaceutical, Inc.'s patent record in context - here's where to go next.

Asklepios Biopharmaceutical, Inc.'s lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 100% of its portfolio - see every assignee active in that class. Explore C12N
Ranked #30,893 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Asklepios Biopharmaceutical, Inc. against ART Research AND Technology, L.L.C., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 45.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.